But the challenge in defining the ULN (upper limits of normal) of ALT is the difficulty of including totally healthy subjects without liver diseases, especially MAFLD (Metabolic-Associated Fatty Liver Disease), the leading cause of liver disease worldwide (Tampi et al., 2020). This evidence concerns the gene GPT and liver disorder.